Drugs / 99mTc-MIRC213
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05622240 | Sep 2022 → Dec 2023 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-MIRC213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05622240 ↗ |
| Route | Intravenous | “99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans” NCT05622240 ↗ |